MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-18-2026
Charles River Laboratories International Market Cap 2011-2026 | CRL
As of March 04, 2026 Charles River Laboratories International has a market cap of $ 8.71 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Charles River Laboratories International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.69 B | 8.54 B | 12.5 B | 11 B | 14.6 B | 14.2 B | 7.68 B | 5.81 B | 5.22 B | 3.68 B | 3.61 B | 3.36 B | 2.77 B | 2.05 B | 1.7 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.6 B | 1.7 B | 6.96 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
104 K | $ 2.85 | -3.72 % | $ 92.5 K |  USA |
 |
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
42 B | $ 118.6 | 0.4 % | $ 36.1 B | USA |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Celcuity
CELC
|
399 M | $ 107.62 | -0.63 % | $ 4.25 B | USA |
 |
Fulgent Genetics
FLGT
|
467 M | $ 13.82 | -2.68 % | $ 418 M | USA |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
709 M | $ 27.55 | -1.59 % | $ 765 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 108.44 | 0.16 % | $ 8.94 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
51.1 B | $ 635.29 | -0.22 % | $ 51.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M |  China |
 |
Laboratory Corporation of America Holdings
LH
|
23.9 B | $ 283.19 | -1.07 % | $ 23.6 B | USA |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
Lantheus Holdings
LNTH
|
5.12 B | $ 79.15 | 3.74 % | $ 5.34 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K |  Israel |
 |
Mettler-Toledo International
MTD
|
28.4 B | $ 1 315.61 | -0.56 % | $ 27.1 B |  Schweiz |
|
Biodesix
BDSX
|
92.1 M | $ 15.5 | -1.59 % | $ 2.01 B | USA |
 |
Myriad Genetics
MYGN
|
409 M | $ 5.26 | 4.89 % | $ 487 M | USA |
 |
NeoGenomics
NEO
|
1.48 B | $ 9.53 | 0.26 % | $ 1.22 B | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
National Research Corporation
NRC
|
1.01 B | $ 13.37 | -3.47 % | $ 328 M | USA |
 |
Natera
NTRA
|
5.31 B | $ 206.39 | 3.11 % | $ 20.3 B | USA |
 |
Invitae Corporation
NVTA
|
511 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
3.55 M | $ 1.12 | -1.78 % | $ 1.42 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
23.3 B | $ 208.28 | -0.95 % | $ 23.1 B | USA |
 |
Danaher Corporation
DHR
|
150 B | $ 204.04 | -0.9 % | $ 145 B | USA |
 |
Organovo Holdings
ONVO
|
3.1 M | - | -2.3 % | $ 19.4 M | USA |
 |
OPKO Health
OPK
|
1.21 B | $ 1.22 | -2.02 % | $ 847 M | USA |
 |
Pacific Biosciences of California
PACB
|
498 M | $ 1.51 | -7.1 % | $ 453 M | USA |
 |
Exact Sciences Corporation
EXAS
|
19.5 B | $ 103.38 | 0.02 % | $ 19.5 B | USA |
 |
Bioventus
BVS
|
351 M | $ 8.8 | 0.34 % | $ 551 M | USA |
 |
DarioHealth Corp.
DRIO
|
43.4 M | $ 10.3 | -4.19 % | $ 292 M | Israel |
 |
DexCom
DXCM
|
25.5 B | $ 73.0 | -1.06 % | $ 28.5 B | USA |
 |
PerkinElmer
PKI
|
14.1 B | - | -0.91 % | $ 14.7 B | USA |
 |
Psychemedics Corporation
PMD
|
16.8 M | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
8.7 M | $ 24.78 | 0.38 % | $ 32.2 M | USA |
 |
QIAGEN N.V.
QGEN
|
8.52 B | - | - | $ 10.6 B |  Niderland |
 |
Quotient Limited
QTNT
|
183 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 24.01 | -4.59 % | $ 254 M | China |
 |
Illumina
ILMN
|
16.4 B | $ 129.9 | -2.25 % | $ 20.7 B | USA |
 |
Renalytix AI plc
RNLX
|
22.7 M | - | 5.66 % | $ 22.7 M | Britain |
 |
VolitionRx Limited
VNRX
|
54.8 M | $ 0.2 | -0.74 % | $ 19.2 M |  Singapore |